X-Rx is an early stage biotech company focused on the development of small molecule medicines in inflammation, fibrosis and oncology.
X-Rx combines the power of DNA-encoded libraries with a virtual
development model to discover novel therapeutics for difficult to treat diseases.
Founded in 2012 as a spin out of X-Chem, X-Rx is an early stage biotech company with more than 80 years of combined drug discovery and development experience. X-Rx is focused on the development of small molecule medicines in inflammation, fibrosis and oncology
The X-Rx Advantage
X-Rx holds a collection of high-value targets coupled with access to DNA-encoded libraries and strong competencies in structure-based drug design. X-Rx has the ability to quickly identify tractable lead series on a wide range of targets.
The X-Rx Pipeline
Our portfolio includes our lead program X-165, a novel autotaxin inhibitor, being developed for multiple indications in fibrosis and targets across a number of families with multiple series of chemical starting points.
X-Rx and Mercachem Provide Update on Two Discovery-Stage Oncology Programs
On October 26, 2016, X-Rx, Inc. and Mercachem BV, a leading chemistry CRO with expertise in medicinal and process chemistry, reported progress with two discovery-stage oncology programs from the portfolio of X-Rx. The programs target Mcl1, an anti-apoptotic target that is over-expressed in many liquid and solid tumor types, and TAK1, a member of the mitogen-activated protein kinase family.